BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia
16 September 2019 - 12:30PM
BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, today announces that the Company will be presenting at the
2nd Annual Next Gen Immuno-Oncology Congress, taking place
September 19-20, 2019 at Hilton Garden Inn, Philadelphia Center
City.
Dr. Williams, BriaCell’s President & CEO,
will present the latest clinical findings of the Phase I/IIa
clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a
Combination Study with pembrolizumab [KEYTRUDA®; manufactured by
Merck & Co., Inc. (NYSE: MRK)]. The Combination Study is listed
in ClinicalTrials.gov as NCT03328026.
BriaCell had hypothesized that combining
Bria-IMT™, which “puts the foot on the gas” of the immune system,
with immune “checkpoint inhibitors”, such as KEYTRUDA®, which act
by “awakening” a component of the immune system, would lead to more
powerful anti-cancer activity compared to that of Bria-IMT™ alone
in advanced breast cancer patients. Initial efficacy data for
the first six patients of the Combination Study, announced on April
3, 2019, supports BriaCell’s hypothesis.
Event: 2nd Annual Next Gen Immuno-Oncology
Congress |
|
|
|
Date: |
|
Thursday, September 19, 2019 |
|
|
|
Time: |
|
9:35 am (Eastern Time) |
|
|
|
Location: |
|
Hilton Garden Inn, Philadelphia Center City |
Following the presentation, a copy of the
presentation document will be posted on
https://briacell.com/investor-relations/presentations/
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is currently conducting a Phase I/IIa
clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a
Combination Study with immune checkpoint inhibitors such as
pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc.
(NYSE: MRK)]. The Combination Study is listed in ClinicalTrials.gov
as NCT03328026.
BriaCell and Incyte Corporation (NASDAQ: INCY)
have formed a non-exclusive clinical trial collaboration to
evaluate the effects of combinations of novel clinical candidates.
Under the agreement, Incyte and BriaCell will be evaluating novel
combinations of compounds from Incyte’s development portfolio with
Bria-IMT™ in advanced breast cancer patients.
BriaCell is developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2023 bis Apr 2024